Clinical trial

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516

Study summary

ClinicalTrials.gov

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Nebivolol Normalized identity: nebivolol View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Metoprolol Normalized identity: metoprolol View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Bradykinin Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Saline Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Vitamin C Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE4

Conditions

Prehypertensionunresolved

Hypertensionunresolved

Interventions

NebivololDRUG · verified · RxNorm: nebivolol

MetoprololDRUG · verified · RxNorm: metoprolol

PlaceboDRUG

BradykininOTHER

SalineOTHER

Vitamin COTHER

Sponsors & collaborators

University of Colorado, Boulderlead sponsor

Forest Laboratoriescollaborator

Mapped research locations

BoulderColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01595516 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.